Sorry, you need to enable JavaScript to visit this website.
Skip to main content
  • News
    • Comunicati stampa
    • Company Statements
    • Media Contact
    • Email Alerts
  • Investors
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • Compliance & Transparency
  • Contact Us
    • Our Locations
    • Medical Information
  • Country List
SEARCH
Home

Main navigation

  • Our Company
    • About Incyte Italia
    • Our Team
    • Contatto con i media Italia
  • What We Do
    • Hematology/Oncology
    • Dermatology
    • Our Medicines
    • Partnerships
  • Culture & Careers
  • HCP Resources
  1. Home
  2. What We Do
  3. Our Medicines
  • SEARCH
  • Our Company
    • About Incyte Italia
    • Our Team
    • Contatto con i media Italia
  • What We Do
    • Hematology/Oncology
    • Dermatology
    • Our Medicines
    • Partnerships
  • Culture & Careers
  • HCP Resources
  • News
    • Comunicati stampa
    • Company Statements
    • Media Contact
    • Email Alerts
  • Investors
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • Compliance & Transparency
  • Contact Us
    • Our Locations
    • Medical Information
  • United States

Incyte International Locations

NORTH AMERICA—HEADQUARTERS

DENMARK

ITALY

SPAIN

UNITED KINGDOM

EUROPE—HEADQUARTERS

FINLAND

JAPAN

SWEDEN

AUSTRIA

FRANCE

THE NETHERLANDS

SWITZERLAND

CANADA

GERMANY

NORWAY

PORTUGAL

Close

Interior of a lab
Interior of a lab
Interior of a lab

Our Medicines

  • Oncology Therapies

FOR HEALTHCARE PROFESSIONALS

See below information on the products we are marketing in Italy.

Image of logo for Iclusig(registered trademark) (ponatinib)

Learn more about Iclusig®  
(ponatinib)

For HCPs
Image of logo for MINJUVI(registered trademark) (tafasitamab-cxix) 200mg - for injection, for intravenous use

Learn more about Minjuvi®  
(tafasitamab)

For HCPs
Image of Pemazyre(registered trademark) (pemigatinib) tablets - 13.5mg, 9mg, 4.5 mg

Learn more about Pemazyre® (pemigatinib)

For HCPs
Learn More

About Incyte Italia

HCP Resources
Footer Logo
  • Facebook Icon
  • LinkedIn Icon
  • Twitter Icon
  • Youtube Icon
  • La nostra azienda
    • Incyte Italia
    • La nostra squadra
    • Area Stampa – Italia
  • La nostra missione
    • Ematologia e Oncologia
    • Malattie infiammatorie e autoimmuni
    • I nostri prodotti
    • Collaborazione
  • Cultura e opportunità professionali
  • Risorse per gli operatori sanitari
  • Notizie
    • Comunicati stampa
    • Dichiarazioni aziendali
    • Area Stampa
    • Avvisi e-mail
  • Investitori
    • Eventi e presentazioni
    • Informazioni finanziarie
    • Informazioni sulle scorte
    • Governance
    • Risorse
  • Responsabilità
    • Compliance & transparency
  • Contattaci
    • Le nostre sedi
    • Informazioni mediche
  • Avviso legale
  • Fornitori
  • Mappa del sito
  • Informativa sulla privacy
  • Cookie Policy
Giugno 2024 IT/VI/NP/24/0025© 2012-2026 Incyte.